Nintedanib for the Prevention of Radiation Pneumonia in Unresectable NSCLC

Who May Qualify: - 1\) Men or women who are over 18 years old (including 18 years old) when signing the willing to sign a consent form form; - 2\) Non-small cell lung cancer was confirmed by histology and could not be resected, and EGFR/ALK driver gene was confirmed negative by gene mutation examination; - 3\) At least one measurable lesion with imaging examination (according to RECIST1.1) is examined by spiral CT or MR, and the length and diameter of the lesion are ≥ 10 mm; - 4\) within 3 days before treatment, the score according to ECOG is 0 \~ 1; - 5\) Life expectancy ≥3 months; - 6)The vital organs function well, - 7)The subjects volunteered to join the study and signed the willing to sign a consent form form, with good compliance and cooperation with the follow-up. Who Should NOT Join This Trial: - 1\) Complicated with severe respiratory diseases: pulmonary fibrosis, active tuberculosis, etc. - 2)Persons with mental disorder, blood system diseases, autoimmune conditions (where your immune system attacks your own body)s and serious primary diseases of heart, brain, liver and kidney; - 3\) Hemorrhagic events that require blood transfusion, invasive intervention or hospitalization occur within 3 months before the first administration, or there are bleeding symptoms and need intervention treatment (such as hemoptysis, hematuria and bloody stool), or high-risk factors with bleeding risk (such as tumor surrounding or invading important blood vessels, obvious necrosis or cavity around tumor, esophageal varices, etc.); - 4\) Thrombosis or embolic diseases, abnormal blood coagulation function and bleeding tendency; - 5\) Known or suspected to be allergic to the study drug and its auxiliary materials; - 6\) The baseline pregnancy test of pregnant and lactating women or fertile women is positive. - 7\) According to the researcher's judgment, the subjects have other factors that may lead to the forced termination of this study. Always talk to your doctor about whether this trial is right for you.